Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion type Assertion NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_head.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion description "[Small molecule inhibitors targeting the kinase activity of ALK have proven to be effective therapies in certain ALK-driven malignancies and one such inhibitor, crizotinib, is now approved for the treatment of EML4-ALK-driven, non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_provenance.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion evidence source_evidence_literature NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_provenance.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion SIO_000772 22932897 NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_provenance.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion wasDerivedFrom befree-20140225 NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_provenance.
- NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_assertion wasGeneratedBy ECO_0000203 NP155501.RAMYBxInaiD7_uPFLkDMTK0gvvRegFe-FZG58_MsEbMdI130_provenance.